Amber Therapeutics was founded in 2021 by Aidan Crawley, Tim Denison, Stefan De Wachter and Charles Knowles with a mission to develop and deliver breakthrough neuromodulation therapies that can fundamentally transform outcomes in areas of unmet clinical need. We have since grown into a multidisciplinary team, combining deep medical device experience with a culture and mindset focused on transformational innovation. Amber UI is the company’s first therapy, aiming to restore normal physiological function in women suffering with mixed urinary incontinence.